Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys

WW Yeh, I Rahman, P Hraber, RT Coffey… - Journal of …, 2010 - Am Soc Microbiol
WW Yeh, I Rahman, P Hraber, RT Coffey, D Nevidomskyte, A Giri, M Asmal, S Miljkovic…
Journal of virology, 2010Am Soc Microbiol
While the simian immunodeficiency virus (SIV)-infected rhesus monkey is an important
animal model for human immunodeficiency virus type 1 (HIV-1) infection of humans, much
remains to be learned about the evolution of the humoral immune response in this model. In
HIV-1 infection, autologous neutralizing antibodies emerge 2 to 3 months after infection.
However, the ontogeny of the SIV-specific neutralizing antibody response in mucosally
infected animals has not been defined. We characterized the kinetics of the autologous …
Abstract
While the simian immunodeficiency virus (SIV)-infected rhesus monkey is an important animal model for human immunodeficiency virus type 1 (HIV-1) infection of humans, much remains to be learned about the evolution of the humoral immune response in this model. In HIV-1 infection, autologous neutralizing antibodies emerge 2 to 3 months after infection. However, the ontogeny of the SIV-specific neutralizing antibody response in mucosally infected animals has not been defined. We characterized the kinetics of the autologous neutralizing antibody response to the transmitted/founder SIVmac251 using a pseudovirion-based TZM-bl cell assay and monitored env sequence evolution using single-genome amplification in four rhesus animals that were infected via intrarectal inoculations. We show that the SIVmac251 founder viruses induced neutralizing antibodies at 5 to 8 months after infection. Despite their slow emergence and low titers, these neutralizing antibodies selected for escape mutants that harbored substitutions and deletions in variable region 1 (V1), V2, and V4 of Env. The neutralizing antibody response was initially focused on V4 at 5 to 8 months after infection and then targeted V1/V2 and V4 by 16 months. These findings reveal a striking delay in the development of neutralizing antibodies in SIVmac-infected animals, thus raising questions concerning the suitability of SIVmac251 as a challenge strain to screen AIDS vaccines that elicit neutralizing antibodies as a means to prevent virus acquisition. They also illustrate the capacity of the SIVmac quasispecies to modify antigenic determinants in response to very modest titers of neutralizing antibodies.
American Society for Microbiology